STADA Arzneimittel AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
January 22, 2018 at 05:30 am EST
Share
DGAP Voting Rights Announcement: STADA Arzneimittel AG
STADA Arzneimittel AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
22.01.2018 / 11:25
Dissemination of a Voting Rights Announcement transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
Notification of Major Holdings
1. Details of issuer
STADA Arzneimittel AG
Stadastraße 2-18
61118 Bad Vilbel
Germany
2. Reason for notification
Acquisition/disposal of shares with voting rights
X
Acquisition/disposal of instruments
Change of breakdown of voting rights
Other reason:
3. Details of person subject to the notification obligation
Name:
City and country of registered office:
Bank of America Corporation
Wilmington, DE United States of America (USA)
4. Names of shareholder(s)
holding directly 3% or more voting rights, if different from 3.
N/A
5. Date on which threshold was crossed or reached:
15 Jan 2018
6. Total positions
% of voting rights attached to shares (total of 7.a.)
% of voting rights through instruments (total of 7.b.1 + 7.b.2)
total of both in % (7.a. + 7.b.)
total number of voting rights of issuer
Resulting situation
1.98 %
8.93 %
10.92 %
62,342,440
Previous notification
0.35 %
10.56 %
10.91 %
/
7. Notified details of the resulting situation a. Voting rights attached to shares (Sec.s 33, 34 WpHG)
ISIN
absolute
in %
direct (Sec. 33 WpHG)
indirect (Sec. 34 WpHG)
direct (Sec. 33 WpHG)
indirect (Sec. 34 WpHG)
DE0007251803
0
1,237,239
0.00 %
1.98 %
Total
1,237,239
1.98 %
b.1. Instruments according to Sec. 38 para. 1 No. 1 WpHG
Type of instrument
Expiration or maturity date
Exercise or conversion period
Voting rights absolute
Voting rights in %
Right of Use
N/A
N/A
5,233,389
8.39 %
Right to Recall
N/A
N/A
333,385
0.53 %
Total
5,566,774
8.93 %
b.2. Instruments according to Sec. 38 para. 1 No. 2 WpHG
Type of instrument
Expiration or maturity date
Exercise or conversion period
Cash or physical settlement
Voting rights absolute
Voting rights in %
Swaps
17-SEP-2018 - 30-NOV-2018
N/A
Cash
1,949
0.003 %
Total
1,949
0.003 %
8. Information in relation to the person subject to the notification obligation
Person subject to the notification obligation is not controlled and does itself not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer (1.).
X
Full chain of controlled undertakings starting with the ultimate controlling natural person or legal entity:
Name
% of voting rights (if at least held 3% or more)
% of voting rights through instruments (if at least held 5% or more)
Total of both (if at least held 5% or more)
Bank of America Corporation
%
%
%
NB Holdings Corporation
%
%
%
BofAML Jersey Holdings Limited
%
%
%
BofAML EMEA Holdings 2 Limited
%
%
%
ML UK Capital Holdings Limited
%
%
%
Merrill Lynch International
%
8.93 %
10.92 %
Bank of America Corporation
%
%
%
NB Holdings Corporation
%
%
%
BAC North America Holding Company
%
%
%
Merrill Lynch, Pierce, Fenner & Smith Incorporated
%
%
%
9. In case of proxy voting according to Sec. 34 para. 3 WpHG
Date of general meeting:
Holding position after general meeting:
% (equals voting rights)
10. Other explanatory remarks:
22.01.2018 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de
STADA Arzneimittel AG (STADA) is a global pharmaceutical company that focuses on multisource products. It focuses on three core business segments: Generics offers drugs in the multisource product category, made from readily available, off-patent active ingredients; Brand-Name Products focuses on multisource products that are accessible without active ingredient research and are principally offered to the public in the non-prescription and self-medication product sectors, while Special Pharmaceuticals focuses on products with specific market entry barriers or specialized sales structures, including oncological drugs. STADA generics are sold by numerous subsidiaries in the respective national markets.
STADA Arzneimittel AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution